Enhanced Investments - Financial Portal

Leidos Partnership Deploys MHS GENESIS Overseas in First of Two Planned OCONUS Waves

Published: 2023-10-17 12:00:00 ET

After Successfully Deploying Electronic Health Record to All Primary DOD Locations in the Continental United States, Leidos Partnership Now Deploys MHS GENESIS Globally with Waves LANDSTUHL/LAKENHEATH and at Fort Buchanan and Guantanamo Bay

RESTON, Va., Oct. 17, 2023 /PRNewswire/ -- The Leidos Partnership for Defense Health (LPDH) today announced it successfully delivered the MHS GENESIS electronic health record to an additional 9,000 Department of Defense (DOD) clinicians and providers as part of its first Outside of the Contiguous United States (OCONUS) deployment (Waves LANDSTUHL/LAKENHEATH). The current system deployment spans 10 Military Treatment Facilities (MTFs) across Europe and the United Kingdom. Additionally, LPDH deployed MHS GENESIS to users at Fort Buchanan, Puerto Rico and Guantanamo Bay, Cuba.

"We achieved a major milestone earlier this calendar year when we successfully deployed MHS GENESIS to all primary DOD locations in the United States and we're now thrilled to roll out the system internationally with our first OCONUS deployments in Wave Europe," said Liz Porter, Leidos Health Group President. "We are also on track to deploy to Pacific locations before the end of the year and we continue to refine the system's capabilities along the way to meet our customer's evolving requirements."

LPDH continues to strengthen MHS GENESIS with a focus on furthering the quality of care. In addition to improving overall platform scalability and performance, the partnership made key system improvements. For example, users are now able to query and report immunizations to state registries through improved connectivity with the Centers for Disease Control and Prevention (CDC). Allergy and medication data are also now available within the system's dental solution.

LPDH enhanced MHS Video Connect, the system's virtual health capability, to streamline and improve secure video appointments. New system tools and processes are now available to satisfy annual periodic health assessments and to meet individual medical readiness standards. Finally, the partnership optimized the system's workflow to improve recurring treatments and care for dialysis patients and added an important interface enabling message exchange with overseas MTFs.

LPDH designed and developed MHS GENESIS, the Military Health System's new electronic health record, and has been providing program management and technical expertise to the Program Executive Office Defense Healthcare Management Systems (PEO DHMS) since 2015.

With this latest overseas DOD wave deployment, the MHS GENESIS system is now operational at over 3,500 locations and now reaches over seven million DOD beneficiaries. MHS GENESIS is 91% deployed to DOD garrison facilities and will next deploy to Far East locations in October 2023.

"We're proud of this successful deployment to our first OCONUS waves," noted Chris Ruefer, Deputy Program Executive Officer for DHMS. "We're excited to further enhance patient and provider experiences."

MHS GENESIS is being deployed across the continental United States and overseas through a total of 23 waves, with each wave targeting a specific region. This approach enables the Department of Defense to take full advantage of lessons learned from prior waves to maximize subsequent wave efficiencies.

About Leidos

Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil and health markets. Leidos' 46,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $14.4 billion for the fiscal year ended December 30, 2022. For more information, visit www.leidos.com.

About LPDH

The Leidos Partnership consists of four core partners - Leidos, Oracle Cerner Corporation, Accenture and Henry Schein One - along with approximately 35 supporting businesses. Together, they deliver an integrated, modern, secure health information system that includes an electronic health record system, a dental system, identity management capability, Cybersecurity, and other supporting components. MHS GENESIS will serve as the system of record, providing a single, integrated solution for managing the health and military readiness of the force for DOD and the Department of Veterans Affairs, among other agencies.

Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management's current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the "Risk Factors" set forth in Leidos' Annual Report on Form 10-K for the fiscal year ended December 30, 2022, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

Contact: Melissa Dueñas(571) 526-6850Melissa.L.Duenas@leidos.com

Thomas Doheny(571) 474-4735Dohenyt@leidos.com

Lauren Reddington (202) 924-2226Lauren.A.Reddington@leidos.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-partnership-deploys-mhs-genesis-overseas-in-first-of-two-planned-oconus-waves-301958436.html

SOURCE Leidos

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.